All News
No Special Heart Risk With JAK Inhibitors, Study Finds
Patients taking Janus kinase (JAK) inhibitors for rheumatoid arthritis experienced similar cardiovascular outcomes as those using the tumor necrosis factor (TNF) blocker adalimumab (Humira), analysis of French national registry data indicated.
Read Article
Tofacitinib shows promise in scleroderma
Systemic sclerosis is one of the rarest autoimmune diseases, affecting roughly 100,000 people (primarily women) in the U.S. With no licensed treatments available for this subset of scleroderma patients, rheumatology researchers are searching for opportunities to use resources and technology that have proven beneficial in treating other autoimmune and rheumatic diseases.
Read Article
RheumNow Podcast – “That’s Not My Name” (10.7.2022)
Dr. Jack Cush goes off on "Untitling" (not using proper names/titles) in the clinic, in addition to reports on rheumatologist salaries, new drugs in phase 1-3 development and the range of COVID-19 MSK symptoms -- all from the past week on RheumNow.com.
Read Article
Great and Not So Great (9.30.2022)
This week it's the great and not-so-great on gout, chondrocalcinosis, osteoporosis and misdiagnosis. We are good at many of those things - what's not so great? Let's review the news and journal reports from the past week on RheumNow.
Read Article
Efficacy and Safety of JAK Inhibitors in Psoriatic Disease
There is a growing body of evidence demonstrating efficacy and safety of JAK inhibitors in patients with moderate-to-severe psoriasis and psoriatic arthritis, according to a systematic review in BMC Rheumatology.
CD19 CAR T Cell Therapy in SLE (9.16.2022)
The big news this week: the approval of deucravacitinib (a new class of drug?) for psoriasis; the 2022 ACR guidance on glucocorticoid-induced osteoporosis; a national poll of older adults over the age of 50 who claimed self-reported or doctor-diagnosed arthritis; and much more. Let's review these and other news, journal reports and announcements from this past week.
Read Article
First In Class, TYK2 Inhibitor FDA Approved for Psoriasis
Deucravacitinib (Sotyktu), a first-in-class, oral, selective, allosteric tyrosine kinase 2 (TYK2) inhibitor, is the only approved TYK2 inhibitor worldwide and the first innovation in oral treatment for moderate-to-severe plaque psoriasis in nearly 10 years.
Read Article
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Links:
